Clinical studies in spinal cord injury: Moving towards successful trials

British Journal of Neurosurgery

Volumn 22, Issue 1, 2008, Pages 3-12

  Knafo, S ^a   Choi, D ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Clinical trial; Injury; Regeneration; Spinal cord

Indexed keywords

4 AMINOPYRIDINE; GACYCLIDINE; GANGLIOSIDE GM1; METHYLPREDNISOLONE; MINOCYCLINE; MONOSIALOGANGLIOSIDE; N ACETYLGALACTOSAMINE 4 SULFATASE; NALOXONE; PLACEBO; PROTEIN NOGO; PROTEIN NOGO A; PROTEIN NOGO B; PROTEIN NOGO C; PROTIRELIN; RHO FACTOR; TIRILAZAD; UNCLASSIFIED DRUG;

AUTOTRANSPLANTATION; CELL TRANSPLANTATION; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; NERVE GRAFT; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY ENSHEATHING CELL; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPINAL CORD INJURY; STEM CELL TRANSPLANTATION; SYRINGOMYELIA;

4-AMINOPYRIDINE; ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; POTASSIUM CHANNEL BLOCKERS; RATS; RECOVERY OF FUNCTION; RESEARCH DESIGN; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 38849143390     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.1080/02688690701593595     Document Type: Review

References (81)

1. NSCISC. Spinal cord injury. Facts and figures at a glance. J Spinal Cord Med 2005;28:379-80.
2. Tator CH, Duncan EG, Edmonds VE, Lapczak LI, Andrews DF. Comparison of surgical and conservative management in 208 patients with acute spinal cord injury. Can J Neurol Sci 1987;14:60-9.
3. Tator CH. Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 2006;59:957-82; discussion 982-7.
4. Ramòn y Cajal S. Degeneration and regeneration of the nervous system. London: Oxford University Press, 1928.
5. Bareyre FM, Kerschensteiner M, Raineteau O, et al. The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. Nat Neurosci 2004;7:269-77.
6. McKeon RJ, Schreiber RC, Rudge JS, Silver J. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J Neurosci 1991;11:3398-411.
7. Bundesen LQ, Scheel TA, Bregman BS, Kromer LF. Ephrin-B2 and EphB2 regulation of astrocyte-meningeal fibroblast interactions in response to spinal cord lesions in adult rats. J Neurosci 2003;23:7789-800.
8. Pasterkamp RJ, Anderson PN, Verhaagen J. Peripheral nerve injury fails to induce growth of lesioned ascending dorsal column axons into spinal cord scar tissue expressing the axon repellent Semaphorin3A. Eur J Neurosci 2001;13:457-71.
9. GrandPre T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000;403(6768):439-44.
10. Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000;403(6768):434-9.
11. Wang KC, Koprivica V, Kim JA, et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002;417(6892):941-4.
12. Bracken MB, Collins WF, Freeman DF, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984;251:45-52.
13. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322:1405-11.
14. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997;277:1597-604.
15. Coleman WP, Benzel D, Cahill DW, et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord 2000;13(3):185-99.
16. Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000;93(1 Suppl):1-7.
17. Short DJ, El Masry WS, Jones PW. High dose methylprednisolone in the management of acute spinal cord injury - a systematic review from a clinical perspective. Spinal Cord 2000;38(5):273-86.
18. Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal-cord injury - a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 1991;324(26):1829-38.
19. Geisler FH, Coleman WP, Grieco G, Poonian D. The Sygen multicenter acute spinal cord injury study. Spine 2001;26(24 Suppl):S87-98.
20. Steeves J, Fawcett J, Tuszynski M. Report of international clinical trials workshop on spinal cord injury February 20-21, 2004, Vancouver, Canada. Spinal Cord 2004;42(10):591-7.
21. Lepeintre JF, D'Arbigny P, Mathe JF, et al. Neuroprotective effect of gacyclidine. A multicenter double-blind pilot trial in patients with acute traumatic brain injury. Neurochirurgie 2004;50(2-3 Pt 1):83-95.
22. Lee SM, Yune TY, Kim SJ, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003;20:1017-27.
23. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004;24:2182-90.
24. Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003;126(Pt 7):1628-37.
25. Kwon BK, Fisher CG, Dvorak MF, Tetzlaff W. Strategies to promote neural repair and regeneration after spinal cord injury. Spine 2005;30(17 Suppl):S3-13.
26. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993;10:1-18.
27. Hayes KC, Potter PJ, Wolfe DL, et al. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J Neurotrauma 1994;11:433-46.
28. Potter PJ, Hayes KC, Segal JL, et al. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma 1998;15(10):837-49.
29. DeForge D, Nymark J, Lemaire E, et al. Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial. Spinal Cord 2004;42(12):674-85.
30. van der Bruggen MA, Huisman HB, Beckerman H, et al. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 2001;248(8):665-71.
31. Cardenas DD, Ditunno J, Graziani V, et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord 2007;45(2):158-68.
32. Pitts LH, Ross A, Chase GA, Faden AI. Treatment with thyrotropin- releasing hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma 1995;12:235-43.
33. Reier PJ, Stokes BT, Thompson FJ, Anderson DK. Fetal cell grafts into resection and contusion/compression injuries of the rat and cat spinal cord. Exp Neurol 1992;115:177-88.
34. Falci S, Holtz A, Akesson E, et al. Obliteration of a posttraumatic spinal cord cyst with solid human embryonic spinal cord grafts: first clinical attempt. J Neurotrauma 1997;14(11):875-84.
35. Wirth ED 3rd, Reier PJ, Fessler RG, et al. Feasibility and safety of neural tissue transplantation in patients with syringomyelia. J Neurotrauma 2001;18:911-29.
36. Rapalino O, Lazarov-Spiegler O, Agranov E, et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 1998;4:814-21.
37. Popovich PG, Guan Z, McGaughy V, et al. The neuropathological and behavioural consequences of intraspinal microglial/macrophage activation. J Neuropathol Exp Neurol 2002;61:623-33.
38. Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 2005;3(3):173-81.
39. Cheng H, Cao Y, Olson L. Spinal cord repair in adult paraplegic rats: partial restoration of hind limb function. Science 1996;273(5274):510-13.
40. Lee YS, Hsiao I, Lin VW. Peripheral nerve grafts and aFGF restore partial hindlimb function in adult paraplegic rats. J Neurotrauma 2002;19:1203-16.
41. Levi AD, Dancausse H, Li X, et al. Peripheral nerve grafts promoting central nervous system regeneration after spinal cord injury in the primate. J Neurosurg 2002;96(2 Suppl):197-205.
42. Cheng H, Liao KK, Liao SF, Chuang TY, Shih YH. Spinal cord repair with acidic fibroblast growth factor as a treatment for a patient with chronic paraplegia. Spine 2004;29(14):E284-8.
43. Raisman G. Specialized neuroglial arrangement may explain the capacity of vomeronasal axons to reinnervate central neurons. Neuroscience 1985;14:237-54.
44. Li Y, Field PM, Raisman G. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. Science 1997;277(5334):2000- 2.
45. Li Y, Decherchi P, Raisman G. Transplantation of olfactory ensheathing cells into spinal cord lesions restores breathing and climbing. J Neurosci 2003;23:727-31.
46. Lu J, Feron F, Ho SM, Mackay-Sim A, Waite PM. Transplantation of nasal olfactory tissue promotes partial recovery in paraplegic adult rats. Brain Res 2001;889:344-57.
47. Lu J, Feron F, Mackay-Sim A, Waite PM. Olfactory ensheathing cells promote locomotor recovery after delayed transplantation into transected spinal cord. Brain 2002;125(Pt 1):14-21.
48. Ramer LM, Richter MW, Roskams AJ, Tetzlaff W, Ramer MS. Peripherally-derived olfactory ensheathing cells do not promote primary afferent regeneration following dorsal root injury. Glia 2004;47:189-206.
49. Riddell JS, Enriquez-Denton M, Toft A, Fairless R, Barnett SC. Olfactory ensheathing cell grafts have minimal influence on regeneration at the dorsal root entry zone following rhizotomy. Glia 2004;47:150-67.
50. Feron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005;128(Pt 12):2951-60.
51. Lima C, Pratas-Vital J, Escada P, et al. Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med 2006;29(3):191-203; discussion 204-6.
52. Huang H, Chen L, Wang H, et al. Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J (Engl) 2003;116:1488-91.
53. Dobkin BH, Curt A, Guest J. Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair 2006;20:5-13.
54. Hofstetter CP, Schwarz EJ, Hess D, et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci USA 2002;99:2199-204.
55. Koda M, Okada S, Nakayama T, et al. Hematopoietic stem cell and marrow stromal cell for spinal cord injury in mice. Neuroreport 2005;16:1763-7.
56. Koshizuka S, Okada S, Okawa A, et al. Transplanted hematopoietic stem cells from bone marrow differentiate into neural lineage cells and promote functional recovery after spinal cord injury in mice. J Neuropathol Exp Neurol 2004;63:64-72.
57. Reier PJ. Cellular transplantation strategies for spinal cord injury and translational neurobiology. NeuroRx 2004;1:424-51.
58. McDonald JW, Liu XZ, Qu Y, et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med 1999;5:1410-12.
59. Cummings BJ, Uchida N, Tamaki SJ, et al. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc Natl Acad Sci USA 2005;102:14069-74.
60. Schnell L, Schwab ME. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 1990;343(6255):269-72.
61. Bregman BS, Kunkel-Bagden E, Schnell L, et al. Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 1995;378(6556):498-501.
62. Schweigreiter R, Bandtlow CE. Nogo in the injured spinal cord. J Neurotrauma 2006;23:384-96.
63. Freund P, Schmidlin E, Wannier T, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med 2006;12:790-2.
64. GrandPre T, Li S, Strittmatter SM. Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 2002;417(6888):547-51.
65. Li S, Strittmatter SM. Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci 2003;23:4219-27.
66. Thuret S, Moon LD, Gage FH. Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 2006;7(8):628-43.
67. Dergham P, Ellezam B, Essagian C, et al. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002;22:6570-7.
68. Fournier AE, Takizawa BT, Strittmatter SM. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci 2003;23:1416-23.
69. Moon LD, Asher RA, Rhodes KE, Fawcett JW. Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC. Nat Neurosci 2001;4:465-6.
70. Bradbury EJ, Moon LD, Popat RJ, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002;416(6881):636-40.
71. Fouad K, Schnell L, Bunge MB, et al. Combining Schwann cell bridges and olfactory-ensheathing glia grafts with chondroitinase promotes locomotor recovery after complete transection of the spinal cord. J Neurosci 2005;25:1169-78.
72. Anderson DK, Beattie M, Blesch A, et al. Recommended guidelines for studies of human subjects with spinal cord injury. Spinal Cord 2005;43(8):453-8.
73. Fawcett JW, Curt A, Steeves JD, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007;45(3):190-205.
74. Lammertse D, Tuszynski MH, Steeves JD, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord 2007;45(3):232-42.
75. Steeves JD, Lammertse D, Curt A, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 2007;45(3):206-21.
76. Tuszynski MH, Steeves JD, Fawcett JW, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord 2007;45:222-31.
77. Frankel HL, Hancock DO, Hyslop G, et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. I. Paraplegia 1969;7(3):179-92.
78. Watts J. Controversy in China. Lancet 2005;365(9454):109-10.
79. Guest J, Herrera LP, Qian T. Rapid recovery of segmental neurological function in a tetraplegic patient following transplantation of fetal olfactory bulb-derived cells. Spinal Cord 2006;44(3):135-42.
80. Blight AR, Tuszynski MH. Clinical trials in spinal cord injury. J Neurotrauma 2006;23:586-93.
81. Cohen M, Sheehan T, Herbison G. Content validity and reliability of the international standards for neurological classification of spinal cord injury. Top Spinal Cord Inj Rehab 1996;1:15-31.